Reproducibility of HPV Testing With Two Versions of the Papilloplex High‐Risk HPV Assay
Journal of Medical Virology · 2025
DOI: 10.1002/jmv.70680 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Pui Yan Jenny Chung und 8 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium. Hauptthemen laut MEDLINE: Papillomavirus Infections, Papillomaviridae, Uterine Cervical Neoplasms, Genotyping Techniques. Die Arbeit nennt 18 Literaturangaben. Gefördert von: P.Y.J.C. and M.A.'s institution has received support from VALGENT, as explained in the VALGENT protocol (Arbyn et al, J Clin Virol 2016; 76 (S1): S14-S21). P.Y….
Abstract (Originalsprache)
Validation of HPV tests usable in cervical cancer screening require demonstration of noninferior clinical accuracy and sufficient reproducibility. The Papilloplex HR‐HPV assay [version1] (Genefirst, UK) has been validated only for clinical accuracy. Here, we assessed its reproducibility, aiming to complete the validation process. A panel of 550 cryopreserved cervical cell samples collected from women attending the cervical cancer screening program in Belgium was used to assess the intra‐ and inter‐laboratory reproducibility of Papilloplex HR‐HPV [version1], a full genotyping assay that identifies separately 14 high‐risk HPV (hrHPV) types using multiple probe amplification technology. We assessed whether the reproducibility fulfils validation criteria (lower 95% confidence interval [CI] bound ≥ 87% and κ ≥ 0.50). Subsequently, we compared the concordance between version1 and a new version6 of the assay and between three analysis methods for PCR curve interpretation. Papilloplex HR‐HPV version1 assay showed an excellent reproducibility for hrHPV (97.5% [CI: 95.8%–98.7%], κ = 0.94 for intra‐ and 93.5% [CI: 91.0%–95.4%], κ = 0.85 for inter‐laboratory reproducibility). Concordance analyses exhibited an excellent agreement between two assay versions and between three PCR curve analysis methods. Papilloplex HR‐HPV version1 assay exhibited excellent reproducibility, completing the international validation criteria. Papilloplex HR‐HPV version6 showed excellent concordance with version1 but still lacks clinical validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium.
- CHU Besançon, Centre National de Référence Papillomavirus, Besançon, France.
- Department of Clinical Trials, Sonic Healthcare Benelux - AML, Antwerp, Belgium.
- Université Marie et Louis Pasteur, CHU Besançon, CNRS, Chrono-environnement (UMR 6249), Besançon, France.
- Department of Primary Healthcare, Faculty of Medicine and Health Sciences, University Ghent, Ghent, Belgium.
- Department of Molecular Diagnostics, Sonic Healthcare Benelux - AML, Antwerp, Belgium.
ORCID-Profile: Quentin Lepiller, Jean-Luc Prétet, Marc Arbyn
Förderung
- P.Y.J.C. and M.A.'s institution has received support from VALGENT, as explained in the VALGENT protocol (Arbyn et al, J Clin Virol 2016; 76 (S1): S14-S21). P.Y…
Zitieren
APA
Chung, P. Y. J., Baraquin, A., Jacquot, K., Tkachenka, Y., Puget, L., Lepiller, Q., Broeck, D. V., Prétet, J. L., & Arbyn, M. (2025). Reproducibility of HPV Testing With Two Versions of the Papilloplex High‐Risk HPV Assay. Journal of Medical Virology. https://doi.org/10.1002/jmv.70680
Vancouver
Chung PYJ, Baraquin A, Jacquot K, Tkachenka Y, Puget L, Lepiller Q, et al. Reproducibility of HPV Testing With Two Versions of the Papilloplex High‐Risk HPV Assay. Journal of Medical Virology. 2025. doi:10.1002/jmv.70680
BibTeX
@article{Chung2025,
author = {Chung, Pui Yan Jenny and Baraquin, Alice and Jacquot, Killian and Tkachenka, Yuliya and Puget, Line and Lepiller, Quentin and Broeck, Davy Vanden and Prétet, Jean-Luc and Arbyn, Marc},
title = {Reproducibility of HPV Testing With Two Versions of the Papilloplex High‐Risk HPV Assay},
journal = {Journal of Medical Virology},
year = {2025},
doi = {10.1002/jmv.70680}
}
EUVIMED